1. AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization.
- Author
-
Azzalini, Eros, Tierno, Domenico, Bartoletti, Michele, Barbazza, Renzo, Giorda, Giorgio, Puglisi, Fabio, Cecere, Sabrina Chiara, Losito, Nunzia Simona, Russo, Daniela, Stanta, Giorgio, Canzonieri, Vincenzo, and Bonin, Serena
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *OVARIAN tumors , *BRCA genes , *RETROSPECTIVE studies , *SYMPTOMS , *TRANSFERASES , *TUMORS , *POLYMERASE chain reaction , *LONGITUDINAL method , *ENZYME inhibitors - Abstract
Simple Summary: New therapeutical strategies are needed to improve survival in high-grade serous ovarian cancer (HGSOC) patients. AKT inhibitors are promising agents able to act in synergy with PARP inhibitors and platinum-based therapies, but the subset of patients who could benefit from this approach is still unclear. We analyzed AKT isoforms expression in a retrospective cohort and we identified four AKT expression groups related to patients' survival, tumor morphology and the BRCA status that could help in stratifying patients for future clinical trials. High-grade serous ovarian cancer (HGSOC) is among the deadliest gynecological malignancies. The acquired resistance to platinum-based therapies and the intrinsic heterogeneity of the disease contribute to the low survival rate. To improve patients' outcomes, new combinatorial approaches able to target different tumor vulnerabilities and enhance the efficacy of the current therapies are required. AKT inhibitors are promising antineoplastic agents able to act in synergy with PARP inhibitors, but the spectrum of patients who can benefit from this combination is unclear, since the role of the three different isoforms of AKT is still unknown. Here, we study the expression of AKT isoforms on a retrospective cohort of archive tissue by RT-droplet digital PCR (ddPCR) analyzing their association with the clinicopathological features of patients. Based on AKT1/AKT2 and AKT1/AKT3 ratios, we define four AKT classes which were related to patients' survival, tumor morphology and BRCA1 expression. Moreover, our results show that high AKT3 expression levels were frequently associated with tumors having classic features, a low number of mitoses and the presence of psammoma bodies. Overall, our study obtains new insights on AKT isoforms and their associations with the clinicopathological features of HGSOC patients. These evidences could help to better define the subsets of patients who can benefit from AKT and PARP inhibitors therapy in future clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF